A) Person’s correlation between logki67 and logLAT1 in patient specimens.

<p>B) Pearson’s correlation between logki67 and logLAT2 in patient specimens (n = 19).</p

Time-activity curves of ¹⁸F-FET in xenografts.

<p>Time-activity curves of ¹⁸F-FET in two different mice (M01, M02) presented as SUV_max in the tumor ROI (A) and tumor-to-brain (T/B) ratio (B).</p

Gene expression in patients compared to xenografts.

<p>Relative gene expression in patient GBM_CPH048, the GBM patient panel (n = 19) and xenografts (n = 11). A) Ki67. B) LAT1. C) LAT2. All genes are normalized to housekeeping genes and are relative to human jejunum (jejunum = 100). Values are displayed as geometric mean±95% CI.</p

¹⁸F-FET uptake in xenografts.

<p>A) The relative T/B ratio of SUV_max versus time after tumor engraftment. B) The relative T/B ratio of SUV_mean versus time after tumor engraftment. Values expressed as mean ± SEM in the CPT-11 (n = 5–7) and in the control group (n = 4–7), *<i>p</i><0.05 and **<i>p</i><0.01.</p

Gene expression and ¹⁸F-FET uptake in xenografts.

<p>Univariate linear regression analysis of gene expression (n = 11). A) LAT1 expression relative to T/B ratio of SUV_max. B) LAT2 expression relative to T/B ratio of SUV_max. C) Ki67 expression relative to LAT1. D) Ki67 expression relative to LAT2. E) Ki67 expression relative to T/B ratio of SUV_max. The 95% CI is indicated by the broken lines.</p

HE of xenograft tumor.

<p>A) HE section across a formalin-fixed paraffin-embedded mouse brain showing the GBM tumor 7 weeks after tumor cell injection. B) HE, magnification×20.</p

Fused ¹⁸F-FET PET/CT images.

<p>Fused ¹⁸F-FET MicroPET/CT images showing tumor progression 6–9 weeks after tumor cell injection. Transverse views through the brain of the same mouse. Illustrated in the figure is a ROI_T drawn round the region with maximum tracer uptake and a 4 mm³ ROI_B drawn in the contralateral hemisphere. Scale bar: 0.0–2.0 SUV_max.</p

Ki67 expression in xenografts.

<p>The gene expression of Ki67 the CPT-11 (n = 7) relative to the control group (n = 4). Values expressed as mean ± SEM, <i>p</i> = 0.35.</p

Bioluminescence imaging to monitor treatment response.

<p>A) Representative images of bioluminescence 3–5 weeks after tumour cell injection showing tumour progression in a B20–4.1 mouse and a control mouse. B) Quantification of total flux relative to baseline (week 0). Values are expressed as mean ± SEM after one week of treatment in the control (n = 13), the B20 group (n = 11) and the B20+TB403 group (n = 8); and after two weeks of treatment in the control (n = 9), the B20 (n = 9) and the B20+TB403 group (n = 6). *<i>p</i><0.05</p

Immunohistochemistry of xenograft tumours.

<p>A) Representative IHC images of HE and high magnification of Ki67 (40x) and CD31 (20x). B) Ki67 proliferation index and C) MVD in the control group (n = 11), the B20 group (n = 10) and the B20+TB403 group (n = 7). Mean ± SEM, **p<0.01</p